Xarelto
Bayer submits new Xarelto indications for European approval
January 6, 2011Sales and Marketing Bayer, DVT, Xarelto, atrial fibrillation, deep vein thrombosis, pulmonary embolism, rivaroxaban, stroke prevention
Bayer is seeking European regulatory approval for a batch of new indications for its oral anticoagulant Xarelto. The company is …
Bayer rebrands pharma division
November 10, 2010Medical Communications, Sales and Marketing Bayer Healthcare, Bayer cross, Byaer Schering Pharma, Marijn Dekkers, Xarelto, prix galien
The name Bayer Schering Pharma has been consigned to the corporate dustbin as its parent group institutes a branding shake-up. …
Bayer’s Xarelto hailed at Prix Galien
October 19, 2010Research and Development Firazyr, Xarelto, prix galien
Bayer’s Factor Xa anticoagulant Xarelto scooped the Best Pharmaceutical Agent award at the prestigious Prix Galien ceremony. Xarelto is part …
Pradaxa, Xarelto and apixaban vie for attention
September 6, 2010Research and Development, Sales and Marketing Pradaxa, Xarelto, apixaban, atrial fibrilation
New data has intensified the competition between three rival would-be cardiology blockbusters. Boehringer Ingelheim’s Pradaxa (dabigatran) and Bayer’s Xarelto (rivaroxaban) …
Novel anticoagulants set to lead atrial fibrillation market
July 9, 2010Sales and Marketing Brinavess, Multaq, Pradaxa, Xarelto, apixaban, atrial fibrilation
Novel anticoagulants set to capture the atrial fibrillation market by 2019, according to a new report. Analysts Decision Resources say …
New anti-clotting drugs: stopping the silent killers
June 28, 2010Research and Development, Sales and Marketing Pradaxa, VTE, Xarelto, atrial fibrilation, thrombosis
Blood clots are a major killer, but the threat they pose is poorly understood by the general public compared to …
Study boost for atrial fibrillation drugs
March 17, 2010Research and Development Pradaxa, VTE, Xarelto, apixaban, betrixaban
Two rival drugs have both shown benefits over warfarin in patients with atrial fibrillation, according to new research. Boehringer Ingelheim’s …
Bayer pharma sales overcome European decline
February 26, 2010Sales and Marketing 2009 financials, Bayer, Xarelto
Bayer’s group sales dropped 5% to 31 billion euros in a “difficult year” for the company that saw a drop …
NICE approves Bayer’s Xarelto
April 23, 2009Research and Development Bayer, NICE, Xarelto
NICE has approved Bayer's anti-clotting treatment Xarelto, bringing it into line with Boehringer Ingelheim's rival Pradaxa. Xarelto (rivaroxaban) was assessed …
FDA to review Xarelto safety concerns
March 19, 2009Research and Development, Sales and Marketing Xarelto
Anti-blood clotting drug Xarelto could fail to win approval in the US due to safety concerns. The FDA has convened …
Bayer’s ‘revolutionary’ anticoagulant Xarelto launched
November 4, 2008Sales and Marketing Xarelto
Xarelto, the new anticoagulant treatment from Bayer has been launched in the UK, and is set to be among a …
The Pharmafocus Interview: Martin Dawkins
September 4, 2008Research and Development, Sales and Marketing Bayer, Cancer, NICE, Xarelto, healthcare
Martin Dawkins is an Englishman born and bred, but has spent most of his career working abroad, including the US, …
Bayer Schering blood clotting drug a ‘major leap forward’
December 14, 2007Sales and Marketing Bayer, Xarelto, clot
Bayer Schering says its new blood clotting drug Xarelto is poised to set a new standard of care for post-surgery …
Latest content
FibroFind appoints Lee Borthwick as CEO
